Evidence-Based Coverage Decisions? Primum Non Nocere
Newell E. McElwee 1*,
S. Yin Ho 2,
Kimberly A. McGuigan 3,
Mark L. Horn 4
1 The authors are all with Pfizer Inc. in New York City. Newell McElwee is vice president of U.S. outcomes research in the U.S. Medical Group.
2 S. Yin Ho is senior director of health strategy in the U.S. Planning and Business Development Group.
3 Kimberly McGuigan is director/team leader of the Evidence-based Medicine Center of Excellence, U.S. Outcomes Research, in the U.S. Medical Group.
4 Mark Horn is medical director of the Government Relations Group.
*Corresponding author.
Drug class reviews are blunt tools for medical decision making. The practice of evidence-based medicine is far more than simply systematic reviews: The patient and doctor are integral. Here we highlight areas of evidence-based coverage decision making where greater balance and transparency could serve to improve the current process, and we recommend elements of a more positive approach that could optimize patient outcomes under resource constraints. [Health Affairs 25 (2006): w279-w282 (published online 6 June 2006; 10.1377/hlthaff.25.w279)]
Key Words:
Access To Care, Consumer Issues, Health Reform, Insurance Coverage, Managed Care - Medicaid, Medicaid, Pharmaceuticals, State/Local Issues, Evidence-Based Medicine